MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
7.40
-0.07
-0.94%
Pre Market: 7.31 -0.09 -1.22% 08:00 07/25 EDT
OPEN
7.37
PREV CLOSE
7.47
HIGH
7.57
LOW
7.32
VOLUME
1
TURNOVER
0
52 WEEK HIGH
7.95
52 WEEK LOW
4.030
MARKET CAP
1.53B
P/E (TTM)
-6.9360
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 2d ago
Weekly Report: what happened at BCRX last week (0715-0719)?
Weekly Report · 3d ago
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
BioCryst Pharmaceuticals, Inc. Develops complement-mediated and rare disease treatments. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues. The drug's FDA approval and international expansion drive BCRX's revenue growth. Despite high leverage, BCRx has a reasonable pathway to deleveraging through Orladesyo's future growth.
Seeking Alpha · 4d ago
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
NASDAQ · 6d ago
Weekly Report: what happened at BCRX last week (0708-0712)?
Weekly Report · 07/15 09:03
The five-year returns have been strong for BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders despite underlying losses increasing
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) share price has soared 102% in the last half decade. The stock has added US$130m to its market cap in the past week. The company has grown revenue at a rate of 51% per year over the last decade. Long term shareholders have made a gain of 15% on average over the same period. BioCryst pharmaceuticals seems like a high growth stock for growth investors.
Simply Wall St · 07/12 13:27
Buy Rating Affirmed for BioCryst Amid Strong Orladeyo Market Penetration and Growth Prospects
TipRanks · 07/12 09:07
ORLADEYO® (BEROTRALSTAT) APPROVED IN PERU
Reuters · 07/09 11:01
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.